Finance entity
markets is the sole category represented across all 1 tracked stories. Cipla is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 6.3 in the same window.
Last mentioned: Jun 15, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Cipla is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 6.3 in the same window. Source depth averages 3 original sources per story, versus 2.6 across the same-window beat baseline. Semaglutide appears in 1 tracked Finance story from March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 84 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Semaglutide. Shared-story counts are live from our verified record — not editorial picks.
India's pharmaceutical sector has launched a massive rollout of affordable versions of popular weight-loss medications, targeting the global dominance of high-priced GLP-1 agonists. This move threatens the premium pricing models of Western pharmaceutical giants while significantly expanding patient access in price-sensitive emerging markets.
Semaglutide is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
